tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Drew Jones, 21 are a BUY (77.78%), 6 are a HOLD (22.22%).
Analyst Drew Jones, currently employed at STEPHENS, carries an average stock price target met ratio of 95.45% that have a potential upside of 32.58% achieved within 415 days.
Drew Jones’s has documented 59 price targets and ratings displayed on 12 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on LGND, Ligand Pharmaceuticals at 03-May-2019.
Analyst best performing recommendations are on EXAS (EXACT SCIENCES).
The best stock recommendation documented was for EXAS (EXACT SCIENCES) at 10/31/2017. The price target of $54 was fulfilled within 1 day with a profit of $0.99 (1.8%) receiving and performance score of 18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 24-Mar-2026
$85
5 months 23 days ago
(24-Mar-2026)
51/51 (100%)
$15.41 (22.14%)
294
Buy Since 10-Apr-2025
$105
$-1714.87 (-94.23%)
$85
7 months 27 days ago
(20-Jan-2026)
3/3 (100%)
$2.65 (2.59%)
89
Buy Since 03-Aug-2021
$105
$-1714.87 (-94.23%)
$68
8 months 11 days ago
(05-Jan-2026)
10/10 (100%)
$3.39 (3.34%)
392
Buy Since 09-Jul-2021
$105
$-1714.87 (-94.23%)
$75
9 months 22 days ago
(25-Nov-2025)
16/16 (100%)
$3.87 (3.83%)
607
Buy Since 31-May-2013
$85
9 months 23 days ago
(24-Nov-2025)
20/20 (100%)
$30.28 (55.34%)
240
What Year was the first public recommendation made by Drew Jones?
